

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Waterbury Hospital Health Center</p> <p>2. 64 Robbins Street Waterbury, Connecticut 06721</p>	<p>In accordance with the letter dated February 15, 2011,</p> <p>3. License number 06-02406-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date December 31, 2015</p> <hr/> <p>5. Docket No. 030-01251 Reference No. 06-30218-01</p>
---	--

- | | | |
|---|--|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.500</p> <p>E. Any byproduct material permitted by 10 CFR 31.11</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (North American Scientific, Inc. Model MED 3601; Isotope Products Laboratories Model NES-8412)</p> <p>E. Prepackaged Kits</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1 curie</p> <p>D. 2.5 curies</p> <p>E. 10 millicuries</p> |
|---|--|---|

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
 - E. In vitro studies.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
06-02406-01

Docket or Reference Number
030-01251;06-30218-01

Amendment No. 65

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 64 Robbins Street, Waterbury, Connecticut and 455 Chase Parkway, Waterbury, Connecticut.
11. The Radiation Safety Officer for this license is Gerald J. Randall, M.S.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Bernard Percarpio, M.D.	35.300
Erick A. Hyson, M.D.	35.100; 35.200; 35.500; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction <u>In vitro studies</u>
Anthony R. Carter, M.D.	35.100; 35.200; 35.500; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction <u>In vitro studies</u>
Jeffrey A. Bitterman, M.D.	35.300 <u>In vitro studies</u>
Gerald R. Berg, M.D.	35.100; 35.200; 35.500 35.300, except thyroid carcinoma <u>In vitro studies</u>
Stephen Stein, M.D.	35.100; 35.200; 35.500; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction <u>In vitro studies</u>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
06-02406-01

Docket or Reference Number
030-01251;06-30218-01

Amendment No. 65

Authorized Users

Material and Use

Kenneth S. Allen, M.D.

35.100; 35.200; 35.500
In vitro studies

Anita L. Bourque, M.D.

35.100; 35.200; 35.500
In vitro studies

Duncan Belcher, M.D.

35.100; 35.200; 35.300

Andrew Lawson, M.D.

35.100; 35.200
35.300, except thyroid carcinoma

Marco Verga, M.D.

35.100; 35.200

Joseph Ravalese, III, M.D.

35.300

Kevin G. Kett, M.D.

35.100; 35.200

Mark L. Ruggiero, M.D.


35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
06-02406-01Docket or Reference Number
030-01251;06-30218-01

Amendment No. 65

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated July 28, 2005 [ML052160096]
 - B. Letter dated August 25, 2005 [ML052380456]
 - C. Letter dated September 28, 2005 [ML052920185]
 - D. Letter dated January 30, 2009 [ML090430338]
 - E. Letter dated March 12, 2009 [ML090780240]
 - F. Letter dated May 6, 2009 [ML091320581]
 - G. Letter dated May 11, 2011 [ML111450662]



For the U.S. Nuclear Regulatory Commission

Date May 25, 2011

By

Original signed by Sandra Gabriel

Sandra Gabriel
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406